ADC Therapeutics sets terms for $125m IPO

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review. 

Menarini bags blood cancer drug with $677M Stemline acquisit...

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

J&J defends Darzalex with FDA approval for faster dosing

GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

Merck builds case for six-week Keytruda dosing as FDA starts...